^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMMH-010

    i
    Other names: IMMH-010, YPD-30, IMMH 010, YPD 30, IMMH010, YPD30
    Associations

    News

    Trials
    Company:
    Tianjin Chase Sun Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction. (PubMed, Bioorg Med Chem)
    IMMH-010, as a prodrug of YPD-29B has been approved for clinical phase I by NMPA. We hope these above results could offer a novel perspective for the development of PD-1/PD-L1 small molecule inhibitors.
    Preclinical • Journal
    |
    PD-1 (Programmed cell death 1)
    |
    IMMH-010
    2years
    A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=96, Enrolling by invitation, Tianjin Chasesun Pharmaceutical Co., LTD | N=186 --> 96 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    IMMH-010
    almost3years
    A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=186, Enrolling by invitation, Tianjin Chasesun Pharmaceutical Co., LTD | Unknown status --> Enrolling by invitation | Phase classification: P1/2 --> P1 | N=96 --> 186 | Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Dec 2023
    Enrollment open • Phase classification • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    IMMH-010
    over4years
    Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug. (PubMed, Pharmaceutics)
    We also compared the pharmacokinetic profiles of IMMH-010 in rodents and primates. After oral administration of IMMH-010, the general exposure of active metabolite YPD-29B was slightly lower in primates than in rodents, suggesting that data should be extrapolated cautiously from rodents to humans.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CES1 (Carboxylesterase 1)
    |
    IMMH-010
    over5years
    A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=96, Not yet recruiting, Tianjin Chasesun Pharmaceutical Co., LTD
    Clinical • New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    IMMH-010